Related Experiment Video
Updated: Sep 30, 2025
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Bone-targeted nanoplatform enables efficient modulation of bone tumor microenvironment for prostate cancer bone
Xiangyu Zhang1,2, Qingbin Liu3, Tingting Zhang4
1Postdoctoral of Shandong University of Traditional Chinese Medicine, Jinan, China.
Abstract:
As there is currently no effective therapy for patients with prostate cancer (PCa) bone metastasis, it was stringent to explore the relevant treatment strategies. Actually, the interaction between cancer cells and bone microenvironment plays important role in prostate cancer bone metastasis, especially the Sonic hedgehog protein (SHH) signaling in the bone microenvironment. The SHH promotes osteoblast maturation and osteoblast then secretes RANKL to induce osteoclastogenesis. Herein, this study develops bone-targeting calcium phosphate lipid hybrid nanoparticles (NPs) loaded with docetaxel (DTXL) and SHH siRNA for PCa bone metastasis treatment. For bone targeting purposes, the nanoplatform was modified with alendronate (ALN). (DTXL + siRNA)@NPs-ALN NPs effectively change the bone microenvironment by inhibiting the SHH paracrine and autocrine signaling, enhancing the anti-tumor effects of DTXL. Besides showing good in vitro cellular uptake, the NPs-ALN also inhibited tumor growth both in vitro and in vivo by inducing apoptosis, cell cycle arrest, and autophagy. This DDS comprised of (DTXL + siRNA)-loaded NPs provides an excellent strategy to treat PCa bone metastasis.
Insights
New nanoparticles target prostate cancer bone metastasis by inhibiting Sonic hedgehog signaling and delivering docetaxel. This dual approach enhances anti-tumor effects and shows promise for treating advanced prostate cancer.
Area of Science:
- Oncology
- Nanomedicine
- Biochemistry
Background:
- Prostate cancer (PCa) bone metastasis lacks effective therapies.
- The Sonic hedgehog (SHH) signaling pathway in the bone microenvironment drives PCa bone metastasis by promoting osteoblast and osteoclast activity.
- Targeting the tumor microenvironment is crucial for effective PCa bone metastasis treatment.
Purpose of the Study:
- To develop a bone-targeting nanodrug delivery system (DDS) for treating prostate cancer bone metastasis.
- To co-deliver docetaxel (DTXL) and SHH siRNA using calcium phosphate lipid hybrid nanoparticles modified with alendronate (ALN).
- To investigate the efficacy of the DDS in modulating the bone microenvironment and inhibiting tumor growth.
Main Methods:
- Fabrication of bone-targeting nanoparticles (NPs) co-loaded with DTXL and SHH siRNA, functionalized with alendronate (ALN).
- Evaluation of NPs-ALN for bone targeting, cellular uptake, and inhibition of SHH signaling pathways.
- Assessment of *in vitro* and *in vivo* anti-tumor effects, including apoptosis, cell cycle arrest, and autophagy induction.
Main Results:
- NPs-ALN demonstrated effective bone targeting and cellular uptake.
- The DDS successfully inhibited SHH signaling, both paracrine and autocrine.
- Significant inhibition of tumor growth was observed *in vitro* and *in vivo*, mediated by apoptosis, cell cycle arrest, and autophagy.
Conclusions:
- The developed (DTXL + siRNA)-loaded NPs-ALN DDS is a promising strategy for treating prostate cancer bone metastasis.
- Modulating the bone microenvironment by inhibiting SHH signaling enhances therapeutic efficacy.
- This nanoplatform offers a novel approach to combatting PCa bone metastasis.
